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Introduction
Hyper-IgD and periodic-fever syndrome (HIDS) is a
recessively inherited-autoinflammatory condition caused
by mevalonate-kinase mutations. It is characterized by
early-onset (<1 year of age), 4-6 days-long acute inflam-
matory episodes that typically recur every 4-6 weeks.
The main features during episodes include fever,
lymphadenopathies, rash, headache, abdominal pain,
diarrhea, and a marked acute phase reaction[1,2].
Previous case reports suggested IL-blockade as a potential
therapy. Canakinumab (CAN) is a fully-human, selective
anti-IL-1b monoclonal-antibody (MoAb). Preliminary
clinical and pharmacokinetics (PK) data of CAN-therapy
in active HIDS patients is presented.
Objectives
Primary objective was to assess if CAN reduces the flare-
rate during the treatment period (TP) compared with that
from the historical period (HP). One secondary objective
was to assess the PK and pharmacodynamics of CAN.
Methods
This is a 6-month open-label CAN TP and a follow-up
period lasting until relapse or up to 6-months max.
Patients ≥2 years-old with active HIDS, CRP > 10 mg/
L, and ≥3 febrile acute-flares in a 6-month HP were
included. All received CAN 4 mg/kg (max. 300 mg)
Q6-weeks in TP, with only one dose up-titration to 6
mg/kg (max. 450 mg) if a flare occurred during the
first 6-weeks.CAN concentrations were determined by
ELISA from samples collected at pre-dose, at pre-
specified time points during the first-month, and at
flares. Population PK analysis was performed using
NONMEM®-program.
Results
Nine patients (6F,3M) with a median age of 17.3 years
(5-29 years) were enrolled. The median number of
flares/patient reduced from 5(3-12) during the HP to 0
(0-2) during the TP. Two patients had a total of 3 flares
during the TP and both required dose up-titrated, with
no flares afterwards during the TP. Seven out of 9
patients flared during the follow-up period at a median
of 110 days (62-196) after the last CAN dose. Population
PK analysis showed that serum clearance of CAN and
its volume of distribution were dependent on body-
weight. The estimated apparent serum clearance (CL/F)
of CAN was 0.20 ± 0.041 L/day and the corresponding
volume of distribution (Vss/F) was 11.6 L. Following the
first dose, the mean (SD) observed Cmax was 30.4 ± 8.13
μg/mL. Apparently weight normalized PK parameters
were similar to those observed in other diseases.
Adverse events (AE) were reported in eight patients,
most were mild (76%) or moderate (18%), and none led
to CAN discontinuation. Infections, mostly involving the
respiratory tract, were the most common type of AE
reported. Two patients reported a serious AE (1 HIDS
flare hospitalization, and 1 gastrointestinal infection
bleed and separate peritonitis).
Conclusion
In this small study, CAN decreased the flare-rate sub-
stantially. PK of CAN in HIDS patients was as expected
for a MoAb and the weight normalized PK parameters
were comparable to those observed in other patient
populations. The AEs reported were manageable.
Further study is needed to better define CAN treatment
in HIDS.
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